Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India. Kilitch also boasts of 25 years of quality contract manufacturing service to reputed national and multinational pharmaceutical companies. its sound knowledge about the industry has resulted in the growth of the organizations along with them as a leading contract manufacturing company in the country.

Keeping pace with the increasing demand of its clients for contract manufacturing, Kilitch has added 2 dedicated blocks and is in the process of adding another 3 dedicated fully USFDA / UKMHRA compliant manufacturing facility in Paonta Sahib (North India). All its plants are approved by the local as well as World Health Organization (WHO) for GMP standards. Kilitch has 3 manufacturing facilities spread across India.

Kilitch has over 25 years of experience in product development and manufacturing. It offers a wide spectrum of contract services, providing reliable supply, scientific expertise and bottom line results to meet the development, clinical and commercial outsourcing needs. Kilitch has been engaged in successful tie-ups with over 20 leading pharmaceutical companies -- Ranbaxy Laboratories Limited, Sandoz India Limited, Zydus Cadila, Nicholas Piramal India Limited, USV Limited, Merck Limited to name a few.

In 2010 the company listed its Equity Shares at NSE.

DCGI Approval-- The company has received the DCGI approvals for Ceftriaxone+Tazobactam, Ceftriaxone+Salbactam,Cefipime +Tazobactam and awaiting for approval for the following products, Rabeprazole, Ceftazidime+Tazobactam, Cefoperazone+Tazobactam

Kilitch Drugs (India) Ltd.

Albert David Ltd.

Ind-Swift Laboratories Ltd.

Venus Remedies Ltd.

Nectar Lifesciences Ltd.

MEDICO

Lyka Labs Ltd.

Wanbury Ltd.

Medicamen Biotech Ltd.

Sakar Healthcare Ltd.

Brooks Laboratories Ltd.

Windlas Biotech Ltd.

Bafna Pharmaceuticals Ltd.

Alpa Laboratories Ltd.

Krebs Biochemicals & Industries Ltd.

Market Cap	562 Cr	ROE	5.9%
P/E Ratio(TTM)	40.1	EPS(TTM)	0.0
P/B Ratio	3.4	Dividend Yield	0.0%
Industry P/E	40.0	Book Value	104.1
		Face Value	10.0

Fundamentals